Precision medicine in cardiology is a groundbreaking approach that revolutionizes the way we understand and treat cardiovascular diseases. By meticulously analyzing an individual's unique genetic, molecular, and clinical attributes, precision medicine aims to develop highly personalized strategies for managing heart conditions. This transformative field leverages state-of-the-art technologies like advanced imaging, molecular profiling, and artificial intelligence to decipher the intricate details of a patient's cardiovascular health. Through this approach, clinicians can identify specific genetic markers and molecular signatures, allowing for more precise diagnoses and tailored therapeutic interventions. Precision medicine in cardiology holds the promise of delivering targeted and optimized care, ushering in a new era of cardiovascular health management.
Title : Personalized and precision medicine (PPM) as a unique healthcare model through biodesign-driven translational applications and cardiology-related healthcare marketing to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Beyond weight loss and diabetes control GLP 1 agonists paradigm shift in Cardiovascular care .
Syed Raza, Awali Hospital, Bahrain
Title : Vericiguat Inhibits the Progress of Cardiac Hypertrophy and Prevents Hypertrophy Induced Heart Failure by Multiple Mechanisms
Guo Wei He, TEDA International Cardiovascular Hospital, Tianjin University, China
Title : Coronary revascularization in patients with diabetes: Prospects for stenting in patients with type 1 diabetes and coronary artery disease
Mekhman N Mamedov, National Research Center for Therapy and Preventive Medicine, Russian Federation
Title : STEMI versus acute occlusive myocardial infarction: Which term should we use?
Yochai Birnbaum, Baylor College of Medicine, United States
Title : Chronic angina and the health economics of cardiovascular risk reduction in macro- and microvascular coronary disease
Uwe Peter Tigor, Auxilius Pharma, United States